Funding Opportunities

Recent funding news stories and opportunities are listed below.

If you require support or are considering applying for funding, consider contacting Markel, Bionow's preferred Partner for R&D funding solutions, who offer the expertise required to maximise your success and also discounts for Bionow members.


An overview of the Biomedical Catalyst funding programme, which supports UK businesses to test and develop innovative technologies for health and care

Centauri Therapeutics closes £24 million GBP Series A investment round, with investment from Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund. Funding will...

Bionabu announces first healthtech Dragon’s Den event with a prize worth $20,000 Healthtech start-ups are invited to apply to pitch to a panel of experts, investors, and peers for a chanc...

MedTech company PolyPhotonix has secured a £10m lead investment deal with US company Prevail InfoWorks to undertake FDA-regulated clinical trials in the United States

Gentronix – the UK-based contract research organisation (CRO) that is a leader in the field of genetic toxicology – has raised £700,000 in a funding round led by existing investor Merci...

Funds will be used to develop further multiplexing capabilities and menu expansion in collaboration with Sansure, on the Q-POC™ device • Cooperation Agreement to accelerate regional c...

“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and technology superpower is hugely encouraging news, ...

UK registered businesses can apply for a share of up to £12 million to develop innovative healthcare products, technologies and processes.

QV Bioelectronics (“QV”) – a medical device start-up pioneering a first of its kind electric field therapy implant for the treatment of the most common and aggressive type of brain tum...

The Markel Grants Team provide expert support in writing and securing funding for new product development. Markel have partnered with Bionow for several years, providing expert support and a...

UK registered organisations can apply for a share of up to £18 million to develop innovative healthcare products, technologies, and processes.

Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need Investment round led by Korean-based ...

Our Valued Sponsors & Partners